Open AccessCombination therapy to checkmate Glioblastoma: clinical challenges and advances
Author(s) -
Ghosh Debarati,
Nandi Saikat,
Bhattacharjee Sonali
Publication year - 2018
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1186/s40169-018-0211-8
Subject(s) - medicine , glioblastoma , context (archaeology) , clinical trial , brain tumor , glioma , oncology , combination therapy , disease , pathology , cancer research , paleontology , biology
Abstract Combination therapy is increasingly becoming the cornerstone of current day antitumor therapy. Glioblastoma multiforme is an aggressive brain tumor with a dismal median survival post diagnosis and a high rate of disease recurrence. The poor prognosis can be attributed to unique treatment limitations, which include the infiltrative nature of tumor cells, failure of anti‐glioma drugs to cross the blood–brain barrier, tumor heterogeneity and the highly metastatic and angiogenic nature of the tumor making cells resistant to chemotherapy. Combination therapy approach is being developed against glioblastoma with new innovative combination drug regimens being tested in preclinical and clinical trials. In this review, we discuss the pathophysiology of glioblastoma, diagnostic markers, therapeutic targeting strategies, current treatment limitations, novel combination therapies in the context of current treatment options and the ongoing clinical trials for glioblastoma therapy.